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Parkinson's disease is an incurable neurodegenerative disease. Most cases of the disea
but about 10% of the cases are familial. The genes thus far identiﬁed in Parkinson's dis
Drosophila is ideally suited to study the molecular neuronal cell biology of these geAvailable online xxxx mutations in Parkinson's disease. Flies reproduce quickly, and their elaborate genetic tools in combination with
their small size allow researchers to analyze identiﬁed cells and neurons in large numbers of animals.
Furthermore, fruit ﬂies recapitulatemany of the cellular andmolecular defects also seen in patients, and these de-
fects often result in clear locomotor and behavioral phenotypes, facilitating genetic modiﬁer screens. Hence, Dro-
sophila has played a prominent role in Parkinson's disease research and has provided invaluable insight into the
molecular mechanisms of this disease.
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Parkinson's disease (PD) is the mo mon neurodegenerative
in the world suffer from
ges from 0.01% to 1.2% of
on risk factor for PD and
f this disease is predicted
many of genes that are causative to PD (see below) are very broadly 
expressed also outside of dopaminergic neurons (d'Amora et al., 
2011; Kühn et al., 2004; Mandemakers et al., 2012; Wirdefeldt and 
Bogdanovic, 2001). In humans, mutations in these broadly expressed 
genes lead to the loss of dopaminergic neurons in the brain, but the given that the population ages, the incidence o
to double by 2040 (Gustavsson et al., 2011; Kowal et al., 2013; von function of several other types of cells is likely compromised as well 
(Davie, 2008; Shulman et al., 2011). Hence, studying cellular defects Campenhausen et al., 2005). Several symptomatic treatments for PDdisease relentlessly pro- caused by PD, also outside the dopaminergic system, may yield valuable 
gresses (Athauda and Foltynie, 2014; Ossig and Reichmann, 2015).
Hence, a better understanding of the underlying pathology is needed
to arrive at more powerful disease modifying strategies.
One of the best recognized pathological hallmarks of PD is the loss of
dopaminergic neurons in the substantia nigra (Hirsch et al., 1988;
Schneider andObeso, 2014).Much of the researchhas therefore focused
on strategies to protect these neurons fromdying. Both pharmacological
strategies (e.g. MPTP treatment (Blandini and Armentero, 2012; Bové
and Perier, 2012)), as well as genetic strategies (e.g. POLG mutations
(Dai et al., 2014; Humphrey et al., 2012; Orsucci et al., 2011)), have
been exploited to kill dopaminergic neurons in model organisms, but
it is questionable if the molecular mechanisms that are affected by
these treatments overlap with those that are defective in PD. In fact,etics, KU Leuven, Center for
sease, KU Leuven, Campus
m.
streken).insight into the molecular mechanisms that are at the basis of PD as 
well. It seems then that eventually, the dopaminergic neurons appear 
particularly vulnerable to defects in these pathways—the reasons for 
this are enigmatic—.
Most of the PD cases are of sporadic origin where environmental or 
genetic factors contribute to the development of the disease. About 10%
of the cases are familial and single gene mutations are causative to the 
disease. Much of the research in PD has focused on these familial 
forms. To date 20 PD susceptibility loci have been identiﬁed, and for 
about half, the causative gene has been isolated (Table 1). Most of the 
genes involved in PD are evolutionary conserved, and they can be read-
ily modeled in genetic model organisms, such as fruit ﬂies, where the 
consequence of their loss- or gain-of-function can be studied and 
where genetic and pharmacological modulation of the phenotypes can 
be assessed. Interestingly, numerous connections between sporadic 
and familial forms of the disease exist: eg causative genes to PD are 
misregulated in sporadic forms of the disease (e.g. Parkin or LRRK2 
(Chai and Lim, 2013; Lesage and Brice, 2012)), or typical protein 
aggregates that are often seen in sporadic and familial cases of the 
disease (Lewy bodies) are enriched in alpha-synuclein, a protein that 
is also found mutated in some familial forms (Spillantini et al., 1997).
Table 1
Monogenetic forms of PD and its ﬂy homolog(s). AD, autosomal dominant; AR, autosomal recessive. Adapted from Marras et al. (2012).
Symbol Gene locus Gene Drosophila
homolog
Inheritance Disorder Status and remarks
PARK1 4q21-22 SNCA (Polymeropoulos
et al., 1997)
no homolog AD Early-onset parkinsonism Conﬁrmed
PARK2 6q25.2-q27 PARK2 encoding Parkin
(Kitada et al., 1998)
parkin AR Early onset parkinsonism Conﬁrmed
PARK3 2p13 Unknown – AD Classical parkinsonism Unconﬁrmed
PARK4 4q21-q23 SNCA no homolog AD Early-onset parkinsonism Erroneous locus (identical to PARK1)
PARK5 4p13 UCHL1 Uch AD Classical parkinsonism Unconﬁrmed
PARK6 1p35-p36 PINK1 (Valente
et al., 2004)
pink1 AR Early onset parkinsonism Conﬁrmed
PARK7 1p36 PARK7 encoding DJ-1
(Bonifati et al., 2003)
Dj-1α and dj-1β AR Early onset parkinsonism Conﬁrmed
PARK8 12q12 LRRK2 (Paisán-Ruíz
et al., 2004)
Lrrk AD Classical parkinsonism Conﬁrmed
PARK9 1p36 ATP13A2
(Ramirez et al., 2006)
CG32000 AR Kufor-Rakeb syndrome, a form
of juvenile-onset atypical parkinsonism
with dementia, spasticity and supranuclear
gaze palsy
Conﬁrmed
PARK10 1p32 Unknown – Risk factor Classical parkinsonism Conﬁrmed susceptibility locus
PARK11 2q36-27 Unknown
(maybe GIGYF2)
– AD Late onset parkinsonism Not independently conﬁrmed
PARK12 Xq21-q25 Unknown – Risk factor Classical parkinsonism Conﬁrmed susceptibility locus
PARK13 2p12 HTRA2 HtrA2 AD or risk factor Classical parkinsonism Unconﬁrmed
PARK14 22q13.1 PLA2G6 (Paisan-Ruiz
et al., 2009)
iPLA2-VIA AR Early-onset dystonia-parkinsonism Conﬁrmed
PARK15 22q12-q13 FBXO7 (Shojaee
et al., 2008)
no homolog AR Early-onset parkinsonian-pyramidal syndrome Conﬁrmed
PARK16 1q32 Unknown
(maybe RAB7L1)
– Risk factor Classical parkinsonism Conﬁrmed susceptibility locus
PARK17 16q11.2 VPS35 Vps35 AD Classical parkinsonism Unconﬁrmed
PARK18 6p21.3 EIF4G1 eIF4G AD Late onset parkinsonism Unconﬁrmed
PARK19 1p31.3 DNAJC6 (Edvardson
et al., 2012)
auxillin AR Juvenile-onset parkinsonism Conﬁrmed
PARK20 21q22.11 SYNJ1 (Krebs et al., 2013;
Quadri et al., 2013)
Synj AR Early-onset parkinsonism ConﬁrmedHence, it is believed that by understanding familial PD, wewill also gain
insight into the sporadic forms of the disease.
PDmodelling in ﬂies
Ideal murine models for PD do not exist and this gap has maximally
allowedDrosophila to step in as an important genetic model in the study
of strategies to combat PD. While the fruit ﬂy models also have limita-
tions, they are small and propagate fast, allowing researchers to conduct
elaborate genetic screens formodiﬁer loci (see below); yet ﬂies also har-
bour a complex nervous systemwith several dopaminergic neuron clus-
ters and they are amenable to live imaging, enabling in vivo cell
biological studies (Bier, 2005;White et al., 2010). It is likely that the neu-
ronal connections relevant to PD in humans are likely not highly con-
served in the ﬂy brain. However, the combination of fast and elaborate
geneticswith in depth cell biological andmolecular studies does provide
a rather unique window on the mechanisms and pathways underlying
PD pathogenesis in vivo.
The genes implicated in PD are highly conserved, and for the 14 PD
genes currently identiﬁed, 12 have a ﬂy homolog (Table 1). The two
genes that are not conserved are alpha-synuclein (SNCA) and FBXO7 and
although these genes are not present in the ﬂy genome, the human
versions of these genes with or without pathogenic mutations have
been overexpressed in fruit ﬂy neurons allowing researchers to eval-
uate the defects that are induced and the pathways that are activated
(Table 2). Such an approach may be particularly interesting for SNCA
where 'gain of protein levels', caused by triplications in humans,
have been shown to cause PD as well (Singleton et al., 2003). Overex-
pression models such as the SNCAmodels in ﬂies are ideal to conduct
biochemical and genetic screens, and this approach has been followedin Drosophila as well as in other model organisms. For example TRAP1
was identiﬁed in such a screen (Butler et al., 2012). TRAP1 is amitochon-
drial chaperone that already had been implicated to be phosphorylated
by another PD-protein Pink1 (Costa et al., 2013; Pridgeon et al., 2007;
Zhang et al., 2013). Hence, such interaction screens start to elucidate
common pathways that span several of the PD-relevant genes.
Similar to overexpression models, genetic analyses of almost all
other PD-relevant genes has been undertaken in fruit ﬂies. Loss-of-
function models based on small gene deletions, transposon insertions
or chemically induced mutations to almost all PD-relevant genes have
been created. Likewise, (over)expression of wild type Drosophila or
human versions of the genes or overexpression of pathogenic or
enzymatically impaired variants have been generated. Table 2 shows
an overview of the extended set of mutations and other genetic tools
that have been created to date to study familial PD in ﬂies as well as
antibodies or other strategies used to localize the gene products. Fig. 1
shows the timeline of identiﬁcation of PD genes versus the charac-
terization of the corresponding ﬂy model.
Studies of PD gene function in ﬂies often make use of UAS-Gal4
driven overexpression of pathogenic mutations (Brand and Perrimon,
1993). Such an approach is in several instances probably warranted,
but care needs to be taken as to not misinterpret overexpression
artifacts, such as the induction of pathways that are normally not
being activated (Liu and Lehmann, 2008). The advent of new genome
editing strategies based on CRISPR/Cas9 (Bassett et al., 2013; Gratz
et al., 2013; Ren et al., 2014) or TALENs (J. Liu et al., 2012; Liu et al.,
2014) but also on targeted single strand annealing using MiMIC trans-
posons, is now allowing to very efﬁciently and locally manipulate the
ﬂy genome as to insert tags or pathogenic mutations in PD-relevant
genes (Venken et al., 2011; Vilain et al., 2014). These modiﬁed genes
Table 2
Fly PD models and tools.
Symbol Gene Drosophila
homolog







– Yes (Chen and Feany, 2005; Chen et al.,
2009; Feany and Bender, 2000; Karpinar
et al., 2009; Kontopoulos et al., 2006;
Trinh et al., 2008)
Yes (A30P⁎–A53T⁎ (Feany and Bender,





parkin Yes (Greene et al., 2003;
Pesah et al., 2004;
Whitworth et al., 2005)
Yes (Cha et al., 2005; Greene et al., 2003;
Haywood and Staveley, 2004;
Muñoz-Soriano and Paricio, 2007; Pesah
et al., 2004) (also genomic construct
(Pesah et al., 2004))
Yes (R42P⁎ (Cha et al., 2005), R275W⁎,
G328E⁎(Wang et al., 2007), T187A
(Kim et al., 2008))
Yes (Yang et al., 2006)
PARK5 UCHL1 Uch No No No Yes (Thao et al., 2012;
Tram et al., 2013)
PARK6 PINK1 Pink1 Yes (Clark et al., 2006; Park
et al., 2006)
Yes (Clark et al., 2006; Kim et al., 2008;
Park et al., 2006; Todd and Staveley,
2008; Yang et al., 2006)
Yes (G309D⁎ (Wang et al., 2006), G426D⁎
(genomic construct) (Yun et al., 2008),
G426D⁎–L464P⁎ (Song et al., 2013)
Yes (Park et al., 2006;








et al., 2005; Meulener
et al., 2005; Park et al.,
2005)
Yes (Kim et al., 2005; Menzies et al.,
2005; Meulener et al., 2005; Yang et al.,
2005)
No No
PARK8 LRRK2 Lrrk Yes (Lee et al., 2007; Wang
et al., 2008)
Yes (Dodson et al., 2012; Gehrke et al.,
2010; Imai et al., 2008; Lee et al., 2007;
Lin et al., 2010; Martin et al., 2014;
Matta et al., 2012; Ng et al., 2009;
Venderova et al., 2009) (also genomic
construct (Dodson et al., 2012))
Yes (R1069G⁎–Y1383C⁎–I1915T⁎ (Imai et al.,
2008), I1122V⁎–Y1699C⁎–I2020T⁎




et al., 2010), R1069G⁎ (Gehrke et al., 2010),
G1914S⁎ (Dodson et al., 2012), G2019S⁎
(Matta et al., 2012), G2019S⁎
(Martin et al., 2014))
Yes (Imai et al.,




PARK9 ATP13A2 CG32000 No Yes (Schertel et al., 2013) No No
PARK13 HTRA2 HtrA2 Yes (Tain et al., 2009;
Yacobi-Sharon et al., 2013;
Yun et al., 2008)
Yes (Igaki et al., 2007; Park et al., 2006;
Tain et al., 2009; Whitworth et al., 2008;
Yacobi-Sharon et al., 2013; Yun et al.,
2008) (also genomic construct
(Tain et al., 2009; Yacobi-Sharon
et al., 2013))
Yes (S236C–S266A–G363S⁎–S364A⁎
(Yun et al., 2008) S266A (genomic construct)
(Yacobi-Sharon et al., 2013))
Yes (Igaki et al., 2007;
Khan et al., 2008)
PARK14 PLA2G6 iPLA2-VIA Yes (Malhotra et al., 2009) No No No
PARK15 FBXO7 no
homolog
– Yes (Burchell et al., 2013) Yes (T22M⁎–R378G⁎–R498X⁎ (Burchell
et al., 2013))
–
PARK17 VPS35 Vps35 Yes (Belenkaya et al., 2008;
Franch-Marro et al., 2008;
Korolchuk et al., 2007; Port
et al., 2008)
Yes (Belenkaya et al., 2008; S. Wang
et al., 2014)
Yes (P316S⁎–D620N⁎–L774M⁎ (H.-S. Wang
et al., 2014))
No
PARK18 EIF4G1 eIF4G No No No Yes (Zapata
et al., 1994)
PARK19 DNAJC6 auxillin Yes (Eun et al., 2007;
Hagedorn et al., 2006;
Kandachar et al., 2008)
Yes (Eun et al., 2008; Hagedorn et al.,
2006; Kandachar et al., 2008) (also
genomic construct (Eun et al., 2007))
No Yes (Eun et al., 2008)
PARK20 SYNJ1 Synj Yes (Muñoz-Soriano and
Paricio, 2007; Verstreken
et al., 2003)
Yes (Dickman et al., 2006) (also genomic
construct (Venken et al., 2008))
No Yes (Verstreken
et al., 2003)
⁎ (Over)expression construct with PD-associated mutation.
Fig. 1.Timeline illustrating the generation ofﬂy PDmodels, indicatingwhen theﬁrst humanPD geneswheredescribed above the timeline and thegeneration of theﬁrstDrosophila loss- and
gain-of-function mutant below the timeline.
are now expressed at endogenous levels. Such technology was already
used to tag the endogenous ﬂy LRRK gene with HA for endogenous
protein localization (Vilain et al., 2014) and such approaches will be-
comemore andmoremainstreamas theymore closelymimic gene dos-
age in patients.
Flies are well-suited for “in vivo” cell biological studies related
to pathogenic pathways in PD because such studies can be readily
combinedwith functional in vivo studies andmany genetically identical
animals can be analyzed. For example,mitochondrial activity in thoracic
and larval muscle cells can be effectively assessed using ﬂuorescent and
biochemical assays and the defects observed can be paired with motor
defects such as negative geotaxis or the ability of the ﬂies to ﬂy (Ali
et al., 2011). Similarly, it is possible to use cell type speciﬁc expression
of transgenes to assess neuronal cell biology in combination with
electrophysiology and electron microscopy at neuromuscular junc-
tions or with confocal imaging in dopaminergic neurons in the ﬂy
brain (Brand and Perrimon, 1993; Cao et al., 2013; Engel, 2008;
Ramachandran and Budnik, 2010; White et al., 2010; Zhang and
Stewart, 2010). Flies can also be aged and the defects that are
observed in PD models can be assessed over time. Flies live a relatively
short life (b80 days) which facilitates analyses of nervous system phe-
notypes across the complete lifespan. An important drawback here is
that this time framemay be too short for dysfunctional proteins or pro-
tein aggregates to accumulate, thus not recapitulating this aspect of
pathology. Nonetheless, the expanded repertoire of functional and cell
biological assays in combination with the powerful genetic toolbox is
exceptional, providing a unique inroad into studying the mechanisms
of PD.
Pathways in PD
Familial PD is caused by mutations in different loci, and the identiﬁ-
cation of the genes is not revealing one speciﬁc pathway that is affected.
Similarly, the sporadic factors that are causative to the disease may be
diverse as well. It is therefore critical to study the different genetic
causes of PD as to assess overlap in pathways but also the differences.
Such studies will not only help to identify more effective treatment
options but they will also aid in stratifying the PD patient population.
Misregulation of microRNAs
One of the pathways that is emerging in PD is misregulation of
microRNAs (miRNA) and work in fruit ﬂies suggests LRRK2 may be a
central player in this process. Fly LRRK binds to Argonaute-1, a central
component of the RNA-induced silencing complex (RISC). Further
work has shown that pathogenic LRRK2 inhibits let-7 (a miRNA) and
miR-184 and this results in the upregulation of two transcription factors
E2F1 and DP; a defect connected to locomotor activity defects in ﬂies
(Gehrke et al., 2010). Interestingly, the expression of SNCA mRNA is
negatively regulated by at least two microRNAs, miR-7 and miR-153
(Doxakis, 2010; Junn et al., 2009) and DJ1 and Parkin expression has
also been suggested to be connected to reduced miR-34b/c expression
in late stage PD brain samples (Miñones-Moyano et al., 2011). While
much more work is needed to elucidate which and how miRNAs are
controlling PD-gene expression, the discovery that LRRK2 may more
directly affect the expression and function of miRNAs themselves may
suggest a more direct connection between PD and miRNA function
(Ma et al., 2013; Mouradian, 2012).
Vesicle trafﬁcking defects
Misregulation of the expression of PD genes may have profound
effects on cellular and neuronal function and work in ﬂies has provided
important insight into these mechanisms. In recent years a role for
vesicle trafﬁcking has emerged and several of the genes involved in
PD have been suggested to play an active role in the process. Alpha-synuclein, LRRK2, Vps35, Synaptojanin, Parkin and DNAJC6/auxillin
are directly connected to the process and several of these proteins
have been extensively studied in fruit ﬂies (Dodson et al., 2014;
Korolchuk et al., 2007; Linhart et al., 2014; MacLeod et al., 2013). Inter-
estingly, work in Drosophila is also helping to start elucidating the
connections between these different players; e.g. between SNCA and
Vps35 (Miura et al., 2014) or between LRRK2 and Synaptojanin (Matta
et al., 2012; Verstreken et al., 2003). Indeed, ﬂy and human LRRK2 can
phosphorylate oneof the central players in synaptic vesicle endocytosis:
Endophilin A, and Endophilin A very tightly binds to Synaptojanin
(Ringstad et al., 1997; Verstreken et al., 2002, 2003). Phosphorylation
of EndophilinA affects itsmembrane binding andmembrane remodeling
properties affecting synaptic vesicle recycling (Ambroso et al., 2014;
Matta et al., 2012).While ﬂy Endophilin A is phosphorylated at Serine75,
a residue central in the regulation of Endophilin A-membrane interac-
tions, mammalian Endophilin A was recently shown to be phosphory-
lated at Serine 75 and at Threonine 73 that are located very closely to
one another (Arranz et al., 2014; Matta et al., 2012). It is in this context
interesting to note that Endophilin A is also ubiquitinated by Parkin and
Parkin levels are strongly upregulated in endophilin Amutantmice (Cao
et al., 2014; Trempe et al., 2009). Hence, discoveries in Drosophila are
adding to the network that is emerging around Endophilin A, but how
the function of Endophilin A is connected to the pathogenesis in PD
remains to be elucidated.
Providing additional links between PD and synaptic endocytosis,
work in ﬂies, mice, nematodes and zebraﬁsh indicate the central role
of Synaptojanin in synaptic vesicle uncoating following new vesicle
formation (Cremona et al., 1999; Harris et al., 2000; Van Epps et al.,
2004; Verstreken et al., 2003). Synaptojanin is a phosphoinositide
phosphatase involved in the dephosphorylation of PI(4,5)P2 (Guo
et al., 1999; McPherson et al., 1996), a lipid required for endocytosis
(Jost et al., 1998; Koch and Holt, 2012). The work indicates that the
absence of Synaptojanin function results in strong defects in the refor-
mation of a synaptic vesicle pool following stimulation because of
defects in protein uncoating fromnascent synaptic vesicles. Interestingly,
DNAJC6/auxillin has been implicated in exactly this same process as well
(Ahle and Ungewickell, 1990; Hirst et al., 2008; Scheele et al., 2001;
Ungewickell et al., 1995; Yim et al., 2010), suggesting that this function
is somehow connected to PD-relevant pathways. However, the links
between synaptic vesicle uncoating and neurodegeneration are yet to
be elucidated.
These ﬁndings in fruit ﬂies, but also thework inmany other systems
strongly implicate a group of PD-relevant proteins rather directly in
(synaptic) vesicle trafﬁcking steps (Braschi et al., 2010; Cirnaru et al.,
2014; Gitler et al., 2008; McLean et al., 2000; Piccoli et al., 2011; Soper
et al., 2011; Vargas et al., 2014; Yun et al., 2013). This work
then opens the question as to how defects in vesicle trafﬁcking can
be connected to PD? Vesicle trafﬁcking is closely connected to
autophagy where pre-autophagic membrane vesicles fuse to create
autophagosomes that engulf debris and destine it for degradation
(Ge et al., 2014; Yamamoto et al., 2012). It is conceivable that defects
in this turnover pathway may result in cellular stress as a result of
defects in protein turn over. However, how defects in autophagy
cause cellular dysfunction in speciﬁc cell types remains to be eluci-
dated. Vesicle trafﬁcking defects may also cause altered localization
of membrane bound receptors thus affecting signaling pathways. At
the synapse, defects in vesicle recycling will also lead to defects in
neurotransmitter release, thus causing altered information transfer in
neuronal circuits. In dopaminergic neurons, slower vesicle recycling
would in theory result in less dopamine uptake into synaptic vesicles
and increased cytoplasmic dopamine levels. Dopamine is toxic and
creates reactive oxygen species (ROS) (Lotharius and O'Malley, 2000)
and removing it from the cytoplasm may be protective. In line with
this idea, over expression of the vesicular dopamine transporter is
protective in PD-ﬂy models (Lawal et al., 2010). Hence, several models
that connect defects in vesicle trafﬁcking to cellular survival are
emerging (Esposito et al., 2012), but additional work is needed to
link this process to pathology.
Mitochondrial dysfunction
While vesicle trafﬁcking defects in PD are emerging in recent years,
mitochondrial dysfunction in the disease is recognized since long and
both sporadic and genetic forms of the disease have been connected
to these organelles. Post mortem brain samples from PD patients often
show mitochondrial defects (Arthur et al., 2009; Keeney et al., 2006;
Naydenov et al., 2010), and pesticides or mitochondrial toxins have
been connected to PD-like symptoms in humans and laboratory animals
(Betarbet et al., 2000; Blandini and Armentero, 2012; Bové and Perier,
2012; Langston et al., 1983). In addition, several of the PD-proteins
have also been shown to affect mitochondria, including DJ-1, Pink1
and Parkin. Interestingly, PD-causing mutations in all these genes are
recessive and loss-of-function animals are thus good systems to model
these types of PD. Also here, fruit ﬂy research has made important
contributions. For example DJ-1 mutant Drosophila show compromised
mitochondrial functionwith age (Hao et al., 2010), and these defects are
also seen in DJ-1 mutant mice (Irrcher et al., 2010). Interestingly, also
pink1 and parkinmutant ﬂies show mitochondrial defects that overlap
with the defects seen in the DJ-1 mutants (Hao et al., 2010). Further
work is now needed to connect the role of DJ-1 to the functions of
Pink1 and Parkin in the regulation of mitochondrial function. Further-
more, insight into how such mitochondrial defects would then lead to
neuronal loss, in particular dopaminergic neuron loss is also awaited.
One of the signiﬁcant contributions fruit ﬂy research has made to
our understanding of PD relevant pathways was the discovery of mi-
tochondrial defects in genetic models of familial cases of PD. Parkin
mutant ﬂies, but also pink1mutant ﬂies show abnormally positioned
wings, dented thoraces and locomotor defects (Clark et al., 2006;
Greene et al., 2003; Haywood and Staveley, 2004; Park et al., 2006;
Pesah et al., 2004; Yang et al., 2006). Examination of the ﬂight mus-
cles showed disorganized muscle ﬁbers with enlarged mitochondria,
explaining the thoracic defects. Although the mitochondrial defects
in parkin or pink1 mutants are most obvious in muscle cells that are
energy demanding, other cell types, including the dopaminergic
neurons in the ﬂy brain, also appear to suffer frommitochondrial de-
fects, suggesting loss of these genes results in systemic mitochondri-
al defects, but not all tissues suffer to a similar extend (Clark et al.,
2006; Greene et al., 2003; Haywood and Staveley, 2004; Park et al.,
2006; Pesah et al., 2004; Yang et al., 2006). These early discoveries
have then paved the way to much more elaborate investigations
that have really gone to the core of the mitochondrial defects. In par-
allel, addressing these fundamental questions has also provided
many exciting avenues in potential therapeutic strategies that are
now waiting to be translated.
The similarity between the phenotypes in parkin and pink1 mu-
tant fruit ﬂies is very striking, and also in humans, PD-patients suf-
fering from mutations in the orthologous genes show very similar
early onset and slow disease progression phenotypes (Lohmann et al.,
2003). These strong overlaps in phenotypes suggested that these
genes may act, at least in part, together to protect mitochondria from
being damaged. This idea was ﬁrst tested in fruit ﬂies by showing that
expression of wild type Parkin in a pink1 mutant partially alleviates
the pink1-associated phenotypes. Conversely, expression of Pink1 in a
parkinmutant does not rescue parkin-associated phenotypes, suggesting
that Parkin acts in this role downstream of Pink1 (Clark et al., 2006; Park
et al., 2006). These observations are interesting in light of an emerging
idea that Parkin is needed to the degradation of sick mitochondria by
autophagy (mitophagy) and proteasomal degradation of mitochondrial
components (Kawajiri et al., 2010; Narendra et al., 2009; Vincow et al.,
2013; Yamamoto et al., 2005).
While many questions still remain, work in ﬂies has helped to
elucidate important aspects of this mitochondrial quality controlpathway. Mitochondria undergo constant fusion and ﬁssion, and it
is believed that this process is needed to exchange mitochondrial
material and maintain a healthy mitochondrial pool. It is also
thought that mitochondrial ﬁssion precedes mitochondrial autopha-
gy as to separate the dysfunctional mitochondrial pieces from the
healthy ones. In line with this idea, early work in ﬂies indicated
that increased ﬁssion or decreased fusion restores many of the mito-
chondrial morphological defects seen in pink1 and parkin mutants
(Deng et al., 2008; Poole et al., 2008; Yang et al., 2008). One explana-
tion of these observations is that indeedmore ﬁssion aids the remov-
al of these dysfunctional mitochondria.
Parallel ﬁndings in mammalian cell culture and Drosophila S2 cells
suggest that under conditions where mitochondria are poisoned,
Pink1 is stabilized on the mitochondrial outer membrane as to recruit
Parkin (Korolchuk et al., 2007; D. P. Narendra et al., 2010; Ziviani
et al., 2010). The stabilization of Pink1 then appears to trigger a series
of events that results in the degradation of these sick mitochondria.
Pink1 is a kinase and when Pink1 is stabilized on dysfunctional mito-
chondria, it phosphorylates Miro, a protein that mediates kinesin
dependent mitochondrial transport (S. Liu et al., 2012; Tsai et al.,
2014; Wang et al., 2011). Further work indicates that phosphorylated
Miro is degraded by Parkin, an E3 ubiquitin ligase that is activated by
the E2 conjugase Ube2A/Rad6 in mammalian cells and in ﬂies
(Haddad et al., 2013). Hence, the work conducted both in mammalian
neurons and in ﬂies, suggests that dysfunctional mitochondria fail to
be transported in the cell. Stabilized Pink1 also targets other proteins:
it recruits and phosphorylates Parkin (Shiba-Fukushima et al., 2012)
and ubiquitin (Kane et al., 2014; Kazlauskaite et al., 2014; Koyano
et al., 2014; Shiba-Fukushima et al., 2014), and Parkin then
ubiquitinates mitochondrial targets that tag the organelle for degrada-
tion. The evidence indicates this pathway is implicated inmitochondrial
quality control, but the targets ubiquitinated by Parkin including
Mitofusin (Poole et al., 2010; Ziviani et al., 2010) and VDAC (Geisler
et al., 2010; D. Narendra et al., 2010) also regulate mitochondrial-
endoplasmatic reticulum contacts (Rowland and Voeltz, 2012), further
causing cellular dysfunction.
While this model is appealing, there are however also still a num-
ber of important but unanswered questions. For example, increased
mitochondrial ﬁssion does not rescue the functional defects that
are observed in pink1 mutant mitochondria, indicating that at least
Pink1, also acts in other pathways of mitochondrial activity (Liu
et al., 2011; Vilain et al., 2012). In addition, it has proven challenging
to observe mitochondrial autophagy in vivo in neurons under non-
artiﬁcial conditions, making it difﬁcult to assess the in vivo impor-
tance of the process also during ageing. The recent development of
killer red mitochondria may help to elucidate the process further.
Here, killer red that is expressed in mitochondria creates ROS when
excited and these ROS result in damage and the recruitment of
parkin to these mitochondria (Ashraﬁ et al., 2014). Finally, if Pink1
is required to recruit Parkin to mitochondria to promote mitophagy,
how is the overexpression of Parkin able to rescue the pink1 mutant
phenotypes? Possibly alternative recruitment mechanisms or alter-
native autophagic strategies may exist and become upregulated,
but these mechanisms, if they are relevant, remain to be studied in
this context.
In healthy mitochondria much of the Pink1 protein is proteolyti-
cally cleaved by PARL (Whitworth et al., 2008). However, the re-
maining Pink1 appears to fulﬁll an important function. Work in
mouse Pink1 knock out cells and in pink1 ﬂy mutants indicates enzy-
matic defects in the electron transport chain (ETC) in the inner mito-
chondrial membrane (Gautier et al., 2008; Liu et al., 2011; Morais
et al., 2009). The ETC transports electrons down their electrochemi-
cal gradient to establish a proton gradient over the inner mitochon-
drial membrane and this gradient is used by the mitochondrial
ATPase to produce ATP. In pink1mutant ﬂies and cells, the enzymatic
defects at the level of complex I result in a less negative
mitochondrial membrane potential and less ATP production. Proteo-
mic studies combined with in vivo rescue experiments in ﬂies, mouse
and patient derived cells subsequently provided evidence that pink1
deﬁciency results in defects to couple electron transport between
complex I and ubiquinone (Morais et al., 2014). Both in ﬂies and
mammalian cells, the process of electron transfer at this level is facil-
itated by the phosphorylation of a speciﬁc complex I subunit
NDUFA10, suggesting that therapeutic strategies that target this
site may promote mitochondrial function (Morais et al., 2014;
Pogson et al., 2014). Further supporting this model, in ﬂies, the mito-
chondrial defects in pink1 mutants are rescued by expression of a
yeast protein, NDI1 that is able to bypass electron transport in com-
plex I by feeding electrons straight into complex III (Pogson et al.,
2014; Vilain et al., 2012). Hence, a model emerges where Pink1
double-times between trying to maintaining high mitochondrial
function and, when that fails, mediating Parkin dependent events.
Using ﬂies to ﬁnd new treatments for PD
Future work can now gear towards using this knowledge to start
developing therapeutic strategies, also here, fruit ﬂies have proven
their value. Pink1 has been routinely used as a model, most likely be-
cause of pragmatic reasons: in ﬂies pink1 is on the X-chromosome,
facilitating genetic screens, but also because Pink1 has been intensely
characterized and studied. It is likely that other PD models will follow
in the future as well. Nonetheless, genetic screens in fruit ﬂies and
gene expression proﬁling in pink1 mutants have been very successful
and they also further point to a mitochondrial connection. Indeed, the
loss of Pink1 function activates a metabolic pathway that results in
increased levels of nucleotides that appear to promote mitochondrial
biogenesis, thereby suppressing the mitochondrial defects. Moreover,
it was shown that enhancing nucleotide metabolism either genetically
or using pharmacology is able to protect againstmitochondrial dysfunc-
tion in pink1mutants (Tuﬁ et al., 2014). Further clinical studieswill now
need to be undertaken to assess the applicability of this approach in
therapy.
An effective strategy to identify suppressors of the pink1 associated
defects has been the use of genetic screening in fruit ﬂies. Pink1mutant
ﬂies do notﬂywell, likely because ofmitochondrial defects in themuscle
cells. Dominant suppressor screens then search for second site muta-
tions (other than the pink1mutation) that alleviate the defect in ﬂight.
This is a fast and effective way to identify suppressor loci, but the dis-
advantage is that such screens aim to identify factors that suppress
the mitochondrial defects in pink1mutant muscle cells, not neurons.
Hence, neuron speciﬁc factorsmaybemissed. Nonetheless, such screen-
ing approaches have identiﬁed numerous modiﬁer loci (Esposito et al.,
2013; Fernandes and Rao, 2011; S. Liu et al., 2012; Pogson et al., 2014;
Thomas et al., 2014; Vos et al., 2012; Wu et al., 2013). For example,
an enzyme that is involved in the production of vitamin K2 is a dosage
sensitive modiﬁer of the pink1 defects in ﬂies. While vitamin K2 is
best known for its role in blood coagulation, subsequent work indicated
that vitamin K2 is also abundantly present inmitochondria, and that the
compound acts as an alternative electron carrier molecule. In pink1
mutants, the action of vitamin K2 overcomes the ETC defect and results
again in effective ATP production (Vos et al., 2012). Similarly, other
strategies that improve mitochondrial function, including those that
scavenge the ROS produced by the pink1 mutant mitochondria are
protective. For example GST or removing Aconitase, a major mediator
of ROS-induced toxicity in mitochondria are protective (Esposito et al.,
2013;KimandYim, 2013;Whitworth et al., 2005). In addition, expression
of Ret, TNF receptor-associated protein 1 (TRAP1) and near-infrared
808 nm light all turned out to improve mitochondrial function in
Drosophila pink1 mutants thereby rescuing the cellular and behavioral
defects in these animals (Klein et al., 2014; Vos et al., 2013; Zhang et al.,
2013). These strategies are thus paving the way to a new generation of
therapeutic strategies in Pink1-dependent strategies.Acknowledgments
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